In this articles, researchers assumed a
reverse association between plasma zinc concentration and incidence of
infection and oxidative stresses in SCD patients. The experiment was performed as
randomized controlled trials (RCT) with parallel design. The participated SCD
patients were all adults (from 18- to 47-year-old) with low plasma zinc level.
They were equally divided into two groups, where one intervention group was
treated with supplements Zinc Acetate, while another control group received
placeboes. This was done in a double-blinded manner. Patient’s blood and body
statues were closely monitored during the experiment. The trial last three months
in total and the outcomes clearly supported the hypothesis. As the plasma zinc
level increased significantly in the intervention group, the number of
infection incidences and oxidative stresses were all significantly decreased compared
to those in control group.
it is known that sickle cell disease (SCD) patients are particularly vulnerable
to infectious factors and oxidative stresses, I find that the trial evidence indeed
showed and emphasized the importance of zinc supplement in SCD patients.
Besides this, it also provided a potential possibility to develop a new
treatment scheme for the disease. It should also be appreciated that authors pointed
out the risk of copper deficiency as a side effect due to long-term zinc
supplements intake. However, there are few drawbacks exist. For example, the
total experiment duration is too short, which might result in the conceal of
some underlying risks or crucial information. Additionally, the patient age
group could be considered narrow since it only contained adults. Together these
would contribute to potential minor bias on the result. Nonetheless, according
to the research results, the conclusion that zinc supplement can be beneficial
to SCD patients is undeniable.